Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The relationship between gadolinium enhancement and [18 F]fluorothymidine uptake in brain lesions with the use of hybrid PET/MRI

T. Rohan, P. Hložanka, M. Dostál, T. Kopřivová, T. Macek, V. Vybíhal, HJ. Martin, A. Šprláková-Puková, M. Keřkovský

. 2024 ; 24 (1) : 110. [pub] 20240819

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019312

Grantová podpora
FNBr, 65269705 Ministerstvo Zdravotnictví Ceské Republiky
MUNI/A/1388/2021 Ministerstvo Školství, Mládeže a Tělovýchovy

BACKGROUND: To evaluate and compare the diagnostic power of [18F]FLT-PET with ceMRI in patients with brain tumours or other focal lesions. METHODS: 121 patients with suspected brain tumour or those after brain tumour surgery were enroled in this retrospective study (61 females, 60 males, mean age 37.3 years, range 1-80 years). All patients underwent [18F]FLT-PET/MRI with gadolinium contrast agent application. In 118 of these patients, a final diagnosis was made, verified by histopathology or by follow-up. Agreement between ceMRI and [18F]FLT-PET of the whole study group was established. Further, sensitivity and specificity of ceMRI and [18F]FLT-PET were calculated for differentiation of high-grade vs. low-grade tumours, high-grade vs. low-grade tumours together with non-tumour lesions and for differentiation of high-grade tumours from all other verified lesions. RESULTS: [18F]FLT-PET and ceMRI findings were concordant in 119 cases (98%). On closer analysis of a subset of 64 patients with verified gliomas, the sensitivity and specificity of both PET and ceMRI were identical (90% and 84%, respectively) for differentiating low-grade from high-grade tumours, if the contrast enhancement and [18F]FLT uptake were considered as hallmarks of high-grade tumour. For differentiation of high-grade tumours from low-grade tumours and lesions of nontumorous aetiology (e.g., inflammatory lesions or post-therapeutic changes) in a subgroup of 93 patients by visual evaluation, the sensitivity of both PET and ceMRI was 90%, whereas the specificity of PET was slightly higher (61%) compared to ceMRI (57%). By receiver operating characteristic analysis, the sensitivity and specificity were 82% and 74%, respectively, when the threshold of SUVmax in the tumour was set to 0.9 g/ml. CONCLUSION: We demonstrated a generally very high correlation of [18F]FLT accumulation with contrast enhancement visible on ceMRI and a comparable diagnostic yield in both modalities for differentiating high-grade tumours from low-grade tumours and lesions of other aetiology.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019312
003      
CZ-PrNML
005      
20241024111515.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s40644-024-00761-0 $2 doi
035    __
$a (PubMed)39160578
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rohan, Tomáš $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Jihlavská 20, Brno, 625 00, Czech Republic $u Department of Radiology and Nuclear Medicine, Medical Faculty, Masaryk University, Brno, 625 00, Czechia $1 https://orcid.org/000000027105583X
245    14
$a The relationship between gadolinium enhancement and [18 F]fluorothymidine uptake in brain lesions with the use of hybrid PET/MRI / $c T. Rohan, P. Hložanka, M. Dostál, T. Kopřivová, T. Macek, V. Vybíhal, HJ. Martin, A. Šprláková-Puková, M. Keřkovský
520    9_
$a BACKGROUND: To evaluate and compare the diagnostic power of [18F]FLT-PET with ceMRI in patients with brain tumours or other focal lesions. METHODS: 121 patients with suspected brain tumour or those after brain tumour surgery were enroled in this retrospective study (61 females, 60 males, mean age 37.3 years, range 1-80 years). All patients underwent [18F]FLT-PET/MRI with gadolinium contrast agent application. In 118 of these patients, a final diagnosis was made, verified by histopathology or by follow-up. Agreement between ceMRI and [18F]FLT-PET of the whole study group was established. Further, sensitivity and specificity of ceMRI and [18F]FLT-PET were calculated for differentiation of high-grade vs. low-grade tumours, high-grade vs. low-grade tumours together with non-tumour lesions and for differentiation of high-grade tumours from all other verified lesions. RESULTS: [18F]FLT-PET and ceMRI findings were concordant in 119 cases (98%). On closer analysis of a subset of 64 patients with verified gliomas, the sensitivity and specificity of both PET and ceMRI were identical (90% and 84%, respectively) for differentiating low-grade from high-grade tumours, if the contrast enhancement and [18F]FLT uptake were considered as hallmarks of high-grade tumour. For differentiation of high-grade tumours from low-grade tumours and lesions of nontumorous aetiology (e.g., inflammatory lesions or post-therapeutic changes) in a subgroup of 93 patients by visual evaluation, the sensitivity of both PET and ceMRI was 90%, whereas the specificity of PET was slightly higher (61%) compared to ceMRI (57%). By receiver operating characteristic analysis, the sensitivity and specificity were 82% and 74%, respectively, when the threshold of SUVmax in the tumour was set to 0.9 g/ml. CONCLUSION: We demonstrated a generally very high correlation of [18F]FLT accumulation with contrast enhancement visible on ceMRI and a comparable diagnostic yield in both modalities for differentiating high-grade tumours from low-grade tumours and lesions of other aetiology.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    12
$a nádory mozku $x diagnostické zobrazování $x patologie $x metabolismus $7 D001932
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a pozitronová emisní tomografie $x metody $7 D049268
650    12
$a magnetická rezonanční tomografie $x metody $7 D008279
650    _2
$a mladiství $7 D000293
650    _2
$a předškolní dítě $7 D002675
650    _2
$a dítě $7 D002648
650    _2
$a mladý dospělý $7 D055815
650    _2
$a retrospektivní studie $7 D012189
650    12
$a gadolinium $x farmakokinetika $7 D005682
650    _2
$a kojenec $7 D007223
650    _2
$a kontrastní látky $7 D003287
650    _2
$a radiofarmaka $7 D019275
650    _2
$a multimodální zobrazování $x metody $7 D064847
650    _2
$a dideoxynukleosidy $7 D015224
650    _2
$a senzitivita a specificita $7 D012680
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hložanka, Petr $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Jihlavská 20, Brno, 625 00, Czech Republic $1 https://orcid.org/0000000317409227
700    1_
$a Dostál, Marek $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Jihlavská 20, Brno, 625 00, Czech Republic. dostal.marek@fnbrno.cz $u Department of Biophysics, Medical Faculty, Masaryk University, Brno, 625 00, Czechia. dostal.marek@fnbrno.cz
700    1_
$a Kopřivová, Tereza $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Jihlavská 20, Brno, 625 00, Czech Republic $u Department of Radiology and Nuclear Medicine, Medical Faculty, Masaryk University, Brno, 625 00, Czechia
700    1_
$a Macek, Tomáš $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Jihlavská 20, Brno, 625 00, Czech Republic $u Department of Radiology and Nuclear Medicine, Medical Faculty, Masaryk University, Brno, 625 00, Czechia
700    1_
$a Vybíhal, Václav $u Clinic of Neurosurgery, University Hospital Brno, Brno, 625 00, Czechia $u Clinic of Neurosurgery, Medical Faculty, Masaryk University, Brno, 625 00, Czechia $1 https://orcid.org/0000000251545591
700    1_
$a Martin, Hiroko Jeannette $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Jihlavská 20, Brno, 625 00, Czech Republic
700    1_
$a Šprláková-Puková, Andrea $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Jihlavská 20, Brno, 625 00, Czech Republic $u Department of Radiology and Nuclear Medicine, Medical Faculty, Masaryk University, Brno, 625 00, Czechia $1 https://orcid.org/0000000274150242
700    1_
$a Keřkovský, Miloš $u Department of Radiology and Nuclear Medicine, University Hospital Brno, Jihlavská 20, Brno, 625 00, Czech Republic $u Department of Radiology and Nuclear Medicine, Medical Faculty, Masaryk University, Brno, 625 00, Czechia $1 https://orcid.org/0000000305879897
773    0_
$w MED00173162 $t Cancer imaging : the official publication of the International Cancer Imaging Society $x 1470-7330 $g Roč. 24, č. 1 (2024), s. 110
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39160578 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111508 $b ABA008
999    __
$a ok $b bmc $g 2201883 $s 1231285
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 24 $c 1 $d 110 $e 20240819 $i 1470-7330 $m Cancer imaging : the official publication of the International Cancer Imaging Society $n Cancer Imaging $x MED00173162
GRA    __
$a FNBr, 65269705 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a MUNI/A/1388/2021 $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20241015
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace